Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02156960

Enrollment

100

Registered

2014-06-05

Start date

2014-05-31

Completion date

2022-11-30

Last updated

2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Brief summary

It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic patients.

Interventions

DRUGDenosumab treatment in osteoporotic patients

To examine the effectiveness of denosumab in osteoporotic patients

DRUGTeriparatide treatment in osteoporotic patients

To examine the effectiveness of teriparatide in osteoporotic patients

DRUGDenosumab and teriparatide treatment in osteoporotic patients

To examine the effectiveness of denosumab and teriparatide in osteoporotic patients

Study design

Allocation

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 120 Years

Healthy volunteers

Yes

Inclusion criteria

* Osteoporotic patients

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
Changes of bone mineral density	every 4-6 months	Bone mineral density will be examined every 4-6 months to evaluate the suitability of the drug.

Secondary

Measure	Time frame	Description
Changes of bone turnover markers	every 3-6 months	Bone turnover markers will be examined every 3-6 months to evaluate the suitability of the drug.

Countries

Japan

Contacts

Primary ContactYukio Nakamura, MD, PhD

yxn14@aol.jp+81-263-37-2659

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026